APA

Plevy S., Salzberg B., Van Assche G., Regueiro M., Hommes D., Sandborn W., Hanauer S., Targan S., Mayer L., Mahadevan U., Frankel M. & Lowder J. (20071219). A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. : Gastroenterology.

Chicago

Plevy Scott, Salzberg Bruce, Van Assche Gert, Regueiro Miguel, Hommes Daniel, Sandborn William, Hanauer Stephen, Targan Stephan, Mayer Lloyd, Mahadevan Uma, Frankel Matthew and Lowder James. 20071219. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. : Gastroenterology.

Harvard

Plevy S., Salzberg B., Van Assche G., Regueiro M., Hommes D., Sandborn W., Hanauer S., Targan S., Mayer L., Mahadevan U., Frankel M. and Lowder J. (20071219). A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. : Gastroenterology.

MLA

Plevy Scott, Salzberg Bruce, Van Assche Gert, Regueiro Miguel, Hommes Daniel, Sandborn William, Hanauer Stephen, Targan Stephan, Mayer Lloyd, Mahadevan Uma, Frankel Matthew and Lowder James. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. : Gastroenterology. 20071219.